xxxxxDNA
xxxxxDNA Articles
On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in revenues. Estimates for...
Published:
Last Updated:
Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head. But Biotechs are also a source of safety IF they are winners, and...
Published:
Last Updated:
Below is a snapshot of the key pre-market news that we are focusing on for early pre-market trading this Tuesday: Apple (AAPL) has its Macworld today. CECO Environmental (CECE) announced 14 new...
Published:
According to Reuters, the National Retail Federation and its members are preparing for a slow year. Reuters writes that the FCC has cleared Google (GOOG) to bid in the upcoming auction of wireless...
Published:
Genentech (NYSE: DNA) just announced its earnings were $0.69 EPS on $2.96 billion for the last quarter, and First Call had estimates pegged at $0.67 EPS on revenues of $2.97 Billion. The company...
Published:
Last Updated:
Genentech (NYSE: DNA) is set to report earnings after the close today. First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion. This will also mark the end of the fiscal 2007...
Published:
Last Updated:
Rite Aid Corporation (RAD) Ugly earnings. No turnaround here. Falls to $2.71 from 52-week high of $6.74. MBIA (MBI) Concerns about CDOs being insured here. Falls to $18.84 from 52-week high of...
Published:
These aren’t the only analyst calls we are watching, but these are the top ten that a673b.bigscoots-temp.com is reviewing: AIG (AIG) reiterated Buy at Goldman Sachs. Apple (AAPL) target raised to $249 from...
Published:
According to Reuters, Nikon is seeing a sharp increase in demand from LCD makers. Reuters writes that the housing slump will last through 2009 and some home prices will drop 30%. Reuters reports the...
Published:
MBIA (MBI) Downgrade by Moody’s. Falls to $25.84 from 52-week high of $76.02. Genentech (DNA) FDA rejects key drug. Drops to $65.54 from 52-week high of $89.73. AMD (AMD) More analyst concerns....
Published:
According to the WSJ and other source, the FDA has rejected Genetech’s (DNA) drug Avastin as a breast cancer treatment. Shares are off 9% on the news Douglas A. McIntyre Want to Retire Early? Start...
Published:
According to Reuters, the Henry Paulson said that a plan would be ready this week to spare some homeowners from mortgage resets. Reuters writes that November auto sales were weak with GM’s (GM)...
Published:
It might not be fair to only break out 10 analyst calls from the myriad of calls out there, because there are dozens to hundreds of changes daily. Here are the key calls that 24/7 Wall St. is...
Published:
According to Reuters, China CITIC Bank is bidding to buy a stake in Bear Stearns (BSC) Reuters reports that the National Retail Federation’s survey of its members shows retail sales are expected to...
Published:
Genentech (NYSE:DNA) posted $0.73 EPS vs $0.72 estimates, but revenues were $2.95 Billion versus a $2.93 Billion estimate. It looks like 3 of the 4 major drugs came in under expectations, with...
Published:
Last Updated: